With cancer, time matters.

Designated an FDA Breakthrough Therapy for Non-Muscle Invasive Bladder Cancer, the novel immunotherapy ANKTIVA® activates key killer cells of the body’s natural immune system to attack the bladder cancer, leading to a long-duration of complete response that for some patients exceeds 47 months.¹

Prescribing Information

Patient Contact | Healthcare Provider Contact

ANKTIVA is a potent immunostimulant that unlocks anti-tumor activity and promotes a durable, complete response.

ANKTIVA works by activating the body’s natural immune system to fight disease and provide long-term immune memory against the cancer.

Duration of Complete Response

47+ MONTHS AND ONGOING ¹

Maintenance Therapy

3 YEARS ¹

1. ANKTIVA Package insert. lmmunityBio, Inc.; 2024.

The Power of ANKTIVA

ANKTIVA is an IL-15 receptor alpha that generates IL-15-activated NK, Killer T, and Memory T Cells while avoiding T-reg stimulation

Safety
& Tolerability

Well Tolerated^1,2,3

Treatment-Related AE Deaths 0%^1,2,7

Side Effects Consistent with BCG^2,4,5

Intravesical
Administration

Maintenance Doses in Responders 3 YEARS¹

Efficacy
Profile

Complete Response^1,2

62%	71%
N=77¹ (FDA Efficacy Population)	N=82² (NEJM Evidence)

Cystectomy Free at 24 Months² 84%

Overall Survival at 24 Months² 94%

Prolonged Duration
of Response

Range of DoR¹ 47+ Month
& Ongoing

% with duration ≥12 months¹ 58%

(Exceeds IBCG Recommendations⁸)

% with duration ≥24 months¹ 40%

1. ANKTIVA Package insert. lmmunityBio, Inc. ; 2024. 2. Chamie K, et al. IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. NEJM Evid. 2023 Jan;2(1): EVIDoa2200167. doi: 10.1056/EVIDoa2200167. 3. Suderman J, et al. Re: IL-15 Superagonist NAI in BCG Unresponsive Non-muscle-invasive Bladder Cancer. Eur Ural. 2023 Jun;83(6):581. doi: 10.1016/j.eururo. 2023.01.009. 4. BCG Package insert. Merck & Co., Inc. ; 2022. 5. Chamie K, et al. Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guerin in Bacillus Calmette-Guerin Unresponsive Nonmuscle-lnvasive Bladder Cancer. Ural Pract. 2024 Mar;11(2):367-375. doi: 10.1097/UPJ.0000000000000517. 6. Han KP, et al.. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine. 2011 Dec;56(3):804-10. doi: 10.1016/j.cyto.2011.09.028. 7. One death reported due to a cardiac arrest that was unrelated to N-803 + BCG. 8. Kamat AM, Sylvester RJ, Bbhle A, Palau J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oneel. 2016 Jun 1;34(16):1935-44. doi: 10.1200/ JCO.2015.64.4070.

Patient Stories

Read about patients who participated in the clinical trials for ANKTIVA.

Irv's Journey

He was first diagnosed with bladder cancer in 2016 when on Thanksgiving day he had very concerning symptoms, including blood in his urine, and several tumors on the interior surface of his bladder were removed by his local urologist, who treated him with BCG, but he failed to respond and the tumors came back. He was afraid he was going to lose his bladder.

Wayne’s Journey

Wayne has lived a rich life that includes his wife, two daughters and three grandkids. He describes himself as someone who “just likes people.”

Physicians’ Journey

Listen to the physicians’ journey with their patients using ANKTIVA.

Indication and Important Safety Information

INDICATION AND USAGE: ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

WARNINGS AND PRECAUTIONS: Delaying cystectomy can lead to the development of metastatic bladder cancer, which can be lethal.

CONTRAINDICATIONS: None

DOSAGE AND ADMINISTRATION: For lntravesical Use Only. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours.

USE IN SPECIFIC POPULATIONS: Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS: The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact lmmunityBio at 1-877-ANKTIVA (1-877-265-8482)

ANKTIVA^® is a new choice to help conquer
non-muscle invasive bladder cancer.

For more information, please call 1-877-ANKTIVA